Byung Soo Kim

Busan Veterans Hospital, Busan, Busan, South Korea

Are you Byung Soo Kim?

Claim your profile

Publications (256)582.16 Total impact

  • Cheol Min Joo, Byung Soo Kim
    [Show abstract] [Hide abstract]
    ABSTRACT: This article considers the unrelated parallel machine scheduling problem with sequence- and machine-dependent setup times and machine-dependent processing times. Furthermore, the machine has a production availability constraint to each job. The objective of this problem is to determine the allocation policy of jobs and the scheduling policy of machines to minimize the total completion time. To solve the problem, a mathematical model for the optimal solution is derived, and hybrid genetic algorithms with three dispatching rules are proposed for large-sized problems. To assess the performance of the algorithms, computational experiments are conducted and evaluated using several randomly generated examples.
    Computers & Industrial Engineering 07/2015; 85. DOI:10.1016/j.cie.2015.02.029 · 1.69 Impact Factor
  • Byung Soo Kim, Cheol Min Joo
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the most important operational management problems of a cross docking system is the truck scheduling problem. Cross docking is a logistics management concept in which products delivered to a distribution center by inbound trucks are immediately sorted out, routed and loaded into outbound trucks for delivery to customers. The truck scheduling problem in a multi-door cross docking system considered in this paper comprises the assignment of trucks to dock doors and the determination of docking sequences for all inbound and outbound trucks in order to minimize the total operation time. A mathematical model for optimal solution is derived, and the genetic algorithms (GAs) and the adaptive genetic algorithms (AGAs) as solution approaches with different types of chromosomes are proposed. The performance of the meta-heuristic algorithms are evaluated using randomly generated several examples.
    Asia Pacific Journal of Operational Research 06/2015; 32(03):1550016. DOI:10.1142/S0217595915500165 · 0.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We compared the efficacy of high-dose cytarabine alone to that of intermediate-dose cytarabine combined with anthracyclines as consolidation therapy. Patients enrolled in the Korea University acute myeloid leukemia (AML) registry received remission induction chemotherapy with the same standard induction regimen (idarubicin and cytarabine 3 + 7). Postremission therapy was performed for three or four cycles according to one of the following regimens: high-dose cytarabine (3 g/m(2)) or combination of intermediate-dose cytarabine (1 g/m(2)) with anthracyclines (idarubicin or mitoxantrone). Among the 443 AML patients enrolled in the registry, 145 patients received consolidation chemotherapy. The median overall survival (OS) and relapse-free survival (RFS) in the high-dose cytarabine group were significantly longer than those in the anthracycline combination group (OS, not reached vs. 16.6 months, p = 0.045; RFS, 38.6 months vs. 11.0 months, p = 0.011). The median duration of neutropenia was longer in the anthracycline combination group than in the high-dose cytarabine group (8 vs. 10 days, p = 0.001). This study suggests that high-dose cytarabine consolidation may produce superior outcomes than combination treatment with intermediate-dose cytarabine and anthracyclines and that the addition of anthracyclines during AML consolidation has limited value as compared to cytarabine intensification.
    Annals of Hematology 05/2015; DOI:10.1007/s00277-015-2389-9 · 2.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
    Korean Circulation Journal 05/2015; 45(3):225-33. DOI:10.4070/kcj.2015.45.3.225
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic myelogenous leukemia (CML) chronic phase (CP) patients cannot tolerate a standard dose (400 mg/day) of imatinib mesylate (IM), sometimes needing a reduced dose. This study aimed to find convenient clinical indexes, rather than plasma trough levels of IM, to define the appropriate IM dosage. Seventy CML CP patients who experienced an IM dose reduction, or a temporary cessation, were enrolled from 2002 to 2010. The IM treatment was resumed and maintained at either ≥400 mg in 25 patients (35.7%; group ≥400 mg) or at ≤300 mg in 45 patients (64.3%; group ≤300 mg). The various clinical characteristics of these patients were evaluated. The plasma trough level of IM was monitored in 20 patients from group ≤300 mg. Via multivariate analysis, the IM dosage divided by the body surface area (BSA) was an important index, presupposing a complete cytogenetic response at 12 months (CCyR12). Patients with IM/BSA >206.7 mg/m(2) showed a higher probability of CCyR12 than others. The IM/BSA (221.7 mg/m(2)) in group ≤300 mg was higher than in group ≥400 mg (207.6 mg/m(2)). The sustained response and survival rate of group ≤300 mg was comparable to that of group ≥400 mg. The plasma trough level of IM was significantly correlated with the IM/BSA. Our study suggests that IM dose adjustments, based on IM/BSA, could improve the clinical outcomes in CML CP patients. © 2015 S. Karger AG, Basel.
    Acta Haematologica 04/2015; 134(1):59-68. DOI:10.1159/000369444 · 0.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical course of generalized pustular psoriasis (GPP) is variable and unpredictable. Sufficient data on the clinical course of the disease has not been reported due to its rarity. To investigate the clinical features and course of GPP according to its subtypes, medical records of patients diagnosed with GPP from 2002 to 2012 at two tertiary hospitals were reviewed. The data included patient demographics, associated symptoms, aggravating factors, patterns of relapse and prognosis. Thirty-three patients with GPP were included in our study, with a mean age of 45.6 years and a male : female ratio of 1:1.2. Patients were categorized based on the following subtypes: acute GPP, 21 (63.6%); GPP of pregnancy, two (6.1%); juvenile GPP, three (9.1%); and annular GPP, seven (21.2%). In the acute GPP population, skin lesions cleared within 2 months in 11 (73.3%) patients, and six (40.0%) of these had no relapse. Severe complications, abortion or death, were observed in two patients (100.0%) with GPP of pregnancy. Nineteen (76.0%) of the GPP patients experienced persistence or relapse of skin lesions. The patterns of skin lesions upon relapse included plaques in six patients (31.6%), pustules in eight patients (42.1%), and plaques and pustules in five patients (26.3%). Among acute GPP patients, 16.7% of patients with no relapse had a history of plaque psoriasis. However, 77.8% of patients with persistence and relapse in their clinical course had a history of plaque psoriasis. In conclusion, our study presents the detailed clinical course of GPP by subtype in Korean patients. © 2015 Japanese Dermatological Association.
    The Journal of Dermatology 03/2015; 42(7). DOI:10.1111/1346-8138.12863 · 2.35 Impact Factor
  • Cheol Min Joo, Byung Soo Kim
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, we consider a single machine scheduling problems integrating with deterioration effect and rate-modifying activities (RMAs). The scheduling problem assumes that the machine may have multiple RMAs and each job has the processing time with deterioration effect increased depending upon the gap between recent RMA and starting time of the job. In practical industrial applications, the determination of the number and position of RMAs is a critical issue, because the RMAs recover deteriorated processing time of jobs bringing back to normal processing time. In this paper, we simultaneously determine the schedule of time-dependent deteriorating jobs and the number and positions of RMAs to minimize the makespan. To solve the problem, a mathematical model is derived to obtain the optimal solution and hybrid meta-heuristic algorithms are proposed for the problem. The performance of the algorithms is compared using randomly generated examples.
    Journal of Advanced Mechanical Design Systems and Manufacturing 01/2015; 9(1):JAMDSM0007-JAMDSM0007. DOI:10.1299/jamdsm.2015jamdsm0007 · 0.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The first edition of the Korean treatment guidelines for chronic myelogenous leukemia (CML) was published in 2006. We intend to update those guidelines to include the use of next-generation tyrosine kinase inhibitors (TKIs).
    01/2015; 88(4):406. DOI:10.3904/kjm.2015.88.4.406
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Despite the advances in acute myeloid leukemia (AML) treatment, the prognosis of elderly patients remains poor and no definitive treatment guideline has been established. In the present study, we aimed to evaluate the effectiveness of intensive chemotherapy in elderly AML patients and to determine which subgroup of patients would be most responsive to the therapy. Methods: We retrospectively analyzed 84 elderly patients: 35, 19, and 30 patients were administered intensive chemotherapy, low-dose chemotherapy, and supportive care, respectively. Results: Among those who received intensive chemotherapy, there were 17 cases of remission after induction chemotherapy; treatment-related mortality was 22.9%. The median overall survival was 7.9 months. Multivariate analysis indicated that the significant prognostic factors for overall survival were performance status, fever before treatment, platelet count, blast count, cytogenetic risk category, and intensive chemotherapy. Subgroup analysis showed that intensive chemotherapy was markedly effective in the relatively younger patients (65-70 years) and those with de novo AML, better-to-intermediate cytogenetic risk, no fever before treatment, high albumin levels, and high lactate dehydrogenase levels. Conclusions: Elderly AML patients had better outcomes with intensive chemotherapy than with low-intensity chemotherapy. Thus, appropriate subgroup selection for intensive chemotherapy is likely to improve therapeutic outcome. © 2014 S. Karger AG, Basel.
    Acta Haematologica 12/2014; 133(3):300-309. DOI:10.1159/000362777 · 0.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we report a new chemical inhibitor against HIV-1 with a novel structure and mode of action. The inhibitor, designated as A1836, inhibited HIV-1 replication and virus production with a 50% inhibitory concentration (IC50) of 2.0 µM in an MT-4 cell-based and cytopathic protection antiviral assay, while its 50% cytotoxic concentration (CC50) was much higher than 50 µM. Examination of the effect of A1836 on in vitro HIV-1 reverse transcriptase (RT) and integrase showed that neither were molecular targets of A1836. The characterization and re-infection assay of the HIV-1 virions generated in the presence of A1836 showed that the synthesis of early RT products in the cells infected with the virions was inhibited dose-dependently, due in part to abnormal protein formation within the virions, thus resulting in an impaired infectivity. These results suggest that A1836 might be a novel candidate for the development of a new type of HIV-1 inhibitor.
    BMB reports 11/2014; 48(2). DOI:10.5483/BMBRep.2015.48.2.239 · 1.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Basic fibroblast growth factor (bFGF) is a crucial factor sustaining human pluripotent stem cells (hPSCs). We designed this study to search the substitutive factors other than bFGF for the maintenance of hPSCs by using human placenta-derived conditioned medium without exogenous bFGF (hPCCM-), containing CXCR2 ligands including IL-8 and GROα, which was developed on the basis of our previous studies. Firstly, we confirmed that IL-8 and/or GROα play independent roles to preserve the phenotype of hPSCs. And, we tried CXCR2 blockage of hPSCs in hPCCM- and verified the significant decrease of pluripotency-associated genes expression and the proliferation of hPSCs. Interestingly, CXCR2 suppression of hPSCs in mTeSR™1 containing exogenous bFGF decreased the proliferation of hPSCs with maintaining pluripotency characteristics. Lastly, we found that hPSCs proliferated robustly for more than 35 passages in hPCCM- on a gelatin substratum. As well, the higher CXCR2 expression of hPSCs cultured in hPCCM- than those in mTeSR™1 was observable. Our findings suggest that, CXCR2 and its related ligands might be novel factors comparable to bFGF supporting the characteristics of hPSCs and hPCCM- might be useful for the maintenance of hPSCs as well as for the accurate evaluation of CXCR2 role on hPSCs without the confounding influence of exogenous bFGF.
    Stem Cells and Development 11/2014; 24(8). DOI:10.1089/scd.2014.0381 · 4.20 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoma, especially non-Hodgkin's lymphoma is extremely rare in pregnancy. A 24-year-old pregnant woman was diagnosed with diffuse large B-cell lymphoma (DLBCL), a subgroup of non-Hodgkin's lymphoma, at 24 weeks' gestation, and was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. After 4 cycles of R-CHOP, she delivered a healthy baby via cesarean section at 34 weeks and 5 days' gestation because of preterm contraction-related fetal distress. The patient was administered the remaining 2 cycles of R-CHOP after delivery. Follow-up magnetic resonance imaging and computed tomography showed complete remission. Here, we report a rare case of DLBCL successfully treated with R-CHOP chemotherapy during pregnancy, we also performed a systematic review of literature for similar cases. There were 3 earlier reports of R-CHOP treatment for DLBCL. All cases, including our case, resulted in preterm birth. Together, these findings suggest that R-CHOP chemotherapy for DLBCL in pregnancy may be associated with preterm birth.
    11/2014; 57(6):526-529. DOI:10.5468/ogs.2014.57.6.526
  • [Show abstract] [Hide abstract]
    ABSTRACT: Here, it is shown that graphene oxide (GO) can be utilized as both a cell-adhesion substrate and a growth factor protein-delivery carrier for the chondrogenic differentiation of adult stem cells. Conventionally, chondrogenic differentiation of stem cells is achieved by culturing cells in pellets and adding the protein transforming growth factor-β3 (TGF-β3), a chondrogenic factor, to the culture medium. However, pellets mainly provide cell-cell interaction and diffusional limitation of TGF-β3 may occur inside the pellet both of these factors may limit the chondrogenic differentiation of stem cells. In this study, GO sheets (size = 0.5–1 μm) were utilized to adsorb fibronectin (FN, a cell-adhesion protein) and TGF-β3 and were then incorporated in pellets of human adipose-derived stem cells (hASCs). The hybrid pellets of hASC-GO enhanced the chondrogenic differentiation of hASCs by adding the cell-FN interaction and supplying TGF-β3 effectively. This method may provide a new platform for stem cell culture for regenerative medicine.
    Advanced Functional Materials 11/2014; 24(41). DOI:10.1002/adfm.201400793 · 10.44 Impact Factor
  • Source
    Won‐Moo Hur, Byung‐Soo Kim, Sung‐Jae Park
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this research is to investigate the relationship between coworker incivility, emotional exhaustion, and organizational outcomes measured by job satisfaction, job performance, and turnover intention. Working with a sample of 286 retail bank employees in South Korea, structural equation modeling is employed to test four hypotheses drawing on conservation of resources (COR) theory and affective events theory (AET). According to the analyses, while employee incivility positively affects emotional exhaustion, emotional exhaustion has a negative effect on job satisfaction and job performance. In addition, emotional exhaustion has a positive impact on turnover intention among organizational employees. These results imply that to better understand the relationship between coworker incivility and organizational outcomes, it is necessary to consider emotional exhaustion as an important mediating variable. The theoretical and practical implications of this study are discussed, together with its limitations and future research directions. © 2014 Wiley Periodicals, Inc.
    Human Factors and Ergonomics in Manufacturing 11/2014; DOI:10.1002/hfm.20587 · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Author Summary BACKGROUND: Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL).
    The Oncologist 10/2014; 19(11). DOI:10.1634/theoncologist.2014-0305 · 4.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The complexity and uncertainty in performing emergency logistics response require along-term preparation and planning. In this paper, a stock pre-positioning model is considered to support an emergency disaster relief response against the event of earthquake. In this model, a maximum response time limit, budget availability, multiple item types, and capacity restrictions are considered to maximize the total expected relief demand of disaster areas covered by existing distribution centers. The decision of distribution centers to cover a disaster area and the amount of supplies to be stocked in each distribution center are simultaneously determined based on the model. The proposed model is applied to a real case with 33 disaster areas and 16 distribution centers in Indonesia. Then a sensitivity analysis is performed by changing the budgets and the maximum response time.
    09/2014; 13(3). DOI:10.7232/iems.2014.13.3.297
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In a prospective randomized controlled study, the efficacy and safety of a continuous ambulatory peritoneal dialysis (CAPD) technique has been evaluated using one icodextrin-containing and two glucose-containing dialysates a day. Eighty incident CAPD patients were randomized to two groups; GLU group continuously using four glucose-containing dialysates (n=39) and ICO group using one icodextrin-containing and two glucose-containing dialysates (n=41). Variables related to residual renal function (RRF), metabolic and fluid control, dialysis adequacy, and dialysate effluent cancer antigen 125 (CA125) and interleukin 6 (IL-6) levels were measured. The GLU group showed a significant decrease in mean renal urea and creatinine clearance (-Δ1.2±2.9 mL/min/1.73 m2, P=0.027) and urine volume (-Δ363.6±543.0 mL/day, P=0.001) during 12 months, but the ICO group did not (-Δ0.5±2.7 mL/min/1.73 m2, P=0.266; -Δ108.6±543.3 mL/day, P=0.246). Peritoneal glucose absorption and dialysate calorie load were significantly lower in the ICO group than the GLU group. The dialysate CA125 and IL-6 levels were significantly higher in the ICO group than the GLU group. Dialysis adequacy, β2-microglobulin clearance and blood pressure did not differ between the two groups. The CAPD technique using one icodextrin-containing and two glucose-containing dialysates tends to better preserve RRF and is more biocompatible, with similar dialysis adequacy compared to that using four glucose-containing dialysates in incident CAPD patients. [Clincal Trial Registry, ISRCTN23727549] Graphical Abstract
    Journal of Korean Medical Science 09/2014; 29(9):1217-25. DOI:10.3346/jkms.2014.29.9.1217 · 1.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Total body irradiation (TBI) has traditionally been used in the conditioning regimen for allogenetic hematopoietic stem cell transplantation (alloHCT) from an unrelated donor (u-HCT). However, patients are increasingly receiving a fludarabine-based conditioning regimen without TBI, as it seemed less toxic than TBI. We need to know the clinical results of non-TBI u-HCT treatments. We retrospectively investigated the clinical outcomes of allogenetic hematopoietic cell transplantation (alloHCT) from an unrelated donor without TBI (non-TBI u-HCT) and compared the clinical outcomes of fludarabine-based (FLU group) and cyclophosphamide-ATG (Cy-ATG group) conditioning regimens. Sixty-one patients received the non-TBI conditioning regimen for u-HCT (32 in the FLU group and 29 in the Cy-ATG group). The cumulative incidence of neutrophil engraftment at 30 days, platelet > 20 K/μL at 30 days, acute graft-versus host disease (aGvHD) at 100 days, and chronic GvHD (cGvHD) at 2 years were 87.01%, 65.57%, 35.20%, and 26.64%, respectively. However, transplantation outcomes and overall survival rates did not differ between the FLU and Cy-ATG groups. Only infused CD34+ cells >3 × 106/kg was identified as a favorable factor for survival in the multivariate analysis. In conclusion, non-TBI u-HCT was feasible and there was no difference between the FLU and Cy-ATG groups in terms of transplantation outcomes.
    Leukemia Research 07/2014; 38(7). DOI:10.1016/j.leukres.2014.01.002 · 2.69 Impact Factor
  • Source
    Byung‐Soo Kim, Jiandong Ding
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past decade, stem cell and regenerative medicine has emerged as a very important field in natural sciences and medicine. We have witnessed remarkable progress in this thriving field, as demonstrated by the research articles and reviews in this AFOB Special Issue.
    Biotechnology Journal 07/2014; 9(7). DOI:10.1002/biot.201400336 · 3.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We conducted a prospective multicenter study identifying the role of bortezomib in patients with relapsed or refractory plasma cell myeloma (PCM) in bone resorption and formation via bone turnover markers. A total of 104 patients received at least 1 cycle of bortezomib. Most of them had advanced disease (n = 89). Among them, 75 patients completed 4 cycles of treatment. Most of the patients (81.7%) were treated in combination with steroid. After the 4th cycle treatment, 47 of 75 patients achieved CR, nCR, VGPR, and PR (64.4%), while 26 patients achieved less than PR (35.6%). The proportion of patients who achieved ≥ PR increased as patients received more treatment cycles, reaching 90% after the 8th cycle. DKK-1 levels decreased significantly posttreatment. Bone formation markers (bALP and OC) and osteoclast regulator such as sRANKL also decreased significantly. These findings were observed primarily in patients who received steroid and who had a longer disease duration. While sRANKL demonstrated significant reduction posttreatment, osteoprotegerin (OPG) level did not significantly change posttreatment, resulting in a decreased sRANKL/OPG ratio (P = 0.037). In conclusion, our clinical data suggest that treatment with bortezomib and steroid may rearrange the metabolic balance between osteoblast and osteoclast activities in PCM.
    BioMed Research International 06/2014; 2014:245247. DOI:10.1155/2014/245247 · 2.71 Impact Factor

Publication Stats

3k Citations
582.16 Total Impact Points

Institutions

  • 2011–2015
    • Busan Veterans Hospital
      Busan, Busan, South Korea
    • King Saud University
      Ar Riyāḑ, Ar Riyāḑ, Saudi Arabia
    • Kangbuk Samsung Hospital
      Sŏul, Seoul, South Korea
  • 1993–2015
    • University of Incheon
      • • Department of Industrial and Management Engineering
      • • Department of Information and Telecommunication Engineering
      Sŏul, Seoul, South Korea
    • The Seoul Institute
      Sŏul, Seoul, South Korea
  • 2011–2014
    • University of Seoul
      Sŏul, Seoul, South Korea
  • 2008–2014
    • Hanyang University
      • • Department of Molecular and Life Science
      • • Division of Chemical Engineering and Bioengineering
      Sŏul, Seoul, South Korea
    • Korea Advanced Institute of Science and Technology
      • Department of Electrical Engineering
      Sŏul, Seoul, South Korea
  • 2005–2014
    • Catholic University of Korea
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
    • Korea Medical Research Institute
      Sŏul, Seoul, South Korea
  • 2004–2014
    • Korea University
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
    • Korea Automotive Technology Institute
      Sŏul, Seoul, South Korea
  • 2003–2014
    • Pukyong National University
      • • Division of Systems Management and Engineering
      • • Department of Polymer Engineering
      • • Faculty of Food Science and Biotechnology
      Tsau-liang-hai, Busan, South Korea
    • Sejong University
      • Department of Electronic Engineering
      Sŏul, Seoul, South Korea
  • 1995–2014
    • Seoul National University
      • • Department of Chemical and Biological Engineering
      • • Institute of Chemical Processes
      Sŏul, Seoul, South Korea
  • 2013
    • Yeungnam University
      • Department of Neurosurgery
      Daikyū, Daegu, South Korea
  • 1992–2013
    • Yonsei University
      • • Department of Applied Statistics
      • • Cancer Metastasis Research Center
      • • College of Medicine
      Sŏul, Seoul, South Korea
  • 2012
    • Gwangju OK Hospital
      Gwangju, Gwangju, South Korea
    • Samsung Medical Center
      • Department of Hematology and Oncology
      Sŏul, Seoul, South Korea
  • 2007–2012
    • Auburn University
      • Department of Industrial & Systems Engineering
      Auburn, Alabama, United States
    • Konkuk University
      Sŏul, Seoul, South Korea
  • 2001–2012
    • Seoul Medical Center
      Sŏul, Seoul, South Korea
  • 1997–2011
    • Kyungpook National University
      Daikyū, Daegu, South Korea
  • 2009–2010
    • Pusan National University
      • Department of Mechanical Engineering
      Tsau-liang-hai, Busan, South Korea
    • Gyeongsang National University
      Shinshū, Gyeongsangnam-do, South Korea
    • Inha University
      • Department of Information and Communication Engineering
      Chemulpo, Incheon, South Korea
  • 1990–2010
    • Yonsei University Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 2008–2009
    • Korea Research Institute of Chemical Technology
      Daiden, Daejeon, South Korea
  • 2006
    • CUNY Graduate Center
      New York City, New York, United States
  • 1998–1999
    • University of Michigan
      • Department of Chemical Engineering
      Ann Arbor, Michigan, United States
    • Boston Children's Hospital
      Boston, Massachusetts, United States
  • 1992–1997
    • University of North Carolina at Chapel Hill
      • Department of Biostatistics
      North Carolina, United States